In the Claims:

1. (Amended) A method for inhibiting IL-13 in a patient having ~~treating~~ an asthma related condition ~~in a human~~, comprising

(a) ~~contacting or~~ administering to said patient a pharmaceutical composition comprising an IL-13 inhibiting ~~effective~~ amount of at least one ~~asthma related Ig derived protein~~, anti-IL-13 antibody ~~with, or~~ to, said ~~cell, tissue, organ or animal~~ patient, wherein said ~~asthma related Ig derived protein~~ anti-IL-13 antibody (i) inhibits ~~at least one biological activity of~~ interleukin-13 (IL-13) ~~*in vitro* or *in vivo*;~~ and (ii) specifically binds at least ~~1~~ 3 amino acids of at least one selected from the group consisting of (a) ~~1-10, 10-20,~~ 20-30, 30-40, ~~40-50,~~ 50-60, ~~60-70, 70-80,~~ or 80-90, ~~90-100, 100-110, 110-120, 120-130, 130-140, 140-146, or 14-145~~ of SEQ ID NO:1.

2. A method according to claim 1, wherein said effective amount is 0.01-50 mg/kilogram of said cells, tissue, organ or animal.

3. (Amended) A method according to claim 1, wherein said contacting or said administrating is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, ~~intrarticular,~~ intrabronchial, ~~intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar,~~ intracerebroventricular, ~~intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic,~~ intrapulmonary~~, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual,~~ intranasal, or transdermal.

4. (Canceled).

5. A method according to claim 1, wherein said asthma related condition is selected from at least one of asthma, bronchial inflammation, excess bronchial mucus or plugs, lung tissue damage, eosinophil accumulation, bronchospasm, narrowing of breathing airways, airway hypersensitivity, airway remodeling, associated pulmonary or sinus inflammation leading to at least one of inspatory or expiatory airway wheezing, breathlessness, chest tightness, coughing, dyspnea, burning, airway edema, excess mucus, bronchospasm, tachypnea, tachycardia, cyanosis, allergic rhinitis, infection, allergy; atopic dermatitis, biorhythm abnormalities, Churg-Strauss syndrome, gastroesophageal reflux disease, hay fever, and allergies.

6. (Canceled).

7. (Amended) A method according to claim 1, wherein said anti-IL-13 antibody ~~asthma related Ig derived protein~~ comprises at least one IL-13 binding region.

8. A method according to claim 7, wherein said IL-13 binding region comprises at least one complementarity determing region (CDR).

9. (Amended) A method accoding to claim 1, wherein said anti-IL-13 antibody ~~asthma related Ig derived protein~~ comprises at least a portion of at least one human heavy chain variable region or at least one light chain variable region.

10. (Amended) A method according to claim 1, wherein said anti-IL-13 antibody ~~asthma related Ig derived protein~~ is a substantially human Ig derived protein.

11. (Amended) A method according to claim 1, wherein said anti-IL-13 antibody ~~asthma related Ig derived protein~~ binds said asthma related protein with an affinity of at least one selected from at least 10^{-9} M, at least 10^{-10} M, at least 10^{-11} M, or at least 10^{-12} M.

12. (Canceled).

13. (Canceled).

14. (Canceled).

15. (Canceled).

16. (Canceled).

17. (Canceled).

18. (Canceled).

19. (Canceled).

20. (Canceled).

21. (Canceled).

22. (Amended) A method for inhibiting IL-13 in a patient having ~~treating~~ an asthma related condition ~~in a human~~, comprising

(a) ~~contacting or~~ administering to said patient a pharmaceutical composition comprising an IL-13 inhibiting ~~effective~~ amount of at least one ~~asthma related Ig derived protein~~, anti-IL-13 antibody ~~with, or~~ to, said ~~cell, tissue, organ or animal~~ patient, wherein said ~~asthma related Ig derived protein~~ anti-IL-13 antibody (i) inhibits ~~at least one biological activity of~~ interleukin-13 (IL-13) ~~*in vitro* or *in vivo*;~~ and (ii) specifically binds at least 1-3 amino acids of at least one selected from the group consisting of (a) ~~1-10, 10-20,~~ 20-30, 30-40, ~~40-50,~~ 50-60, ~~60-70, 70-80,~~ or 80-90, ~~90-100, 100-110, 110-120, 120-130, 130-140, 140-146, or 14-145~~ of SEQ ID NO:1, or a mutein thereof, wherein said mutein comprises at least one substitution selected from the groups consisting of at least one of Ile48, Val48, Gln90, Glu90, Leu95, Ile95, Leu96, Ile96, Leu99, Ile99, Phe103, or Tyr103, and at least one substitution selected from Asn130 and~~/or~~ Gln130.

14-24. (Canceled).

Please add the following NEW CLAIMS 25-32:

25. (New) A method according to claim 22, wherein said effective amount is 0.01-50 mg/kilogram of said cells, tissue, organ or animal.

26. (New) A method according to claim 22, wherein said contacting or saidadministrating is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrabronchial, intracerebroventricular, intrapulmonary, intranasal, or transdermal.

27. (New) A method according to claim 22, wherein said asthma related condition is selected from at least one of asthma, bronchial inflammation, excess bronchial mucus or plugs, lung tissue damage, eosinophil accumulation, bronchospasm, narrowing of breathing airways, airway hypersensitivity, airway remodeling, associated pulmonary or sinus inflammation leading to at least one of inspatory or expiatory airway wheezing, breathlessness, chest tightness, coughing, dyspnea, burning, airway edema, excess mucus, bronchospasm, tachypnea, tachycardia, cyanosis, allergic rhinitis, infection, allergy; atopic dermatitis, biorhythm abnormalities, Churg-Strauss syndrome, gastroesophageal reflux disease, hay fever, and allergies.

28. (New) A method according to claim 22, wherein said anti-IL-13 antibody comprises at least one IL-13 binding region.

29. (New) A method according to claim 28, wherein said IL-13 binding region comprises at least one complementarity determing region (CDR).

30. (New) A method accoding to claim 22, wherein said anti-IL-13 antibody comprises at least a portion of at least one human heavy chain variable region or at least one light chain variable region.

31. (New) A method according to claim 22, wherein said anti-IL-13 antibody is a substantially human Ig derived protein.

32. (New) A method according to claim 22, wherein said anti-IL-13 antibody binds said asthma related protein with an affinity of at least one selected from at least 10^{-9} M, at least 10^{-10} M, at least 10^{-11} M, or at least 10^{-12} M.